Puma Biotechnology, Inc. (PBYI) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2026
Loading P/E history...
PBYI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Puma Biotechnology, Inc. (PBYI) trades at a price-to-earnings ratio of 11.9x, with a stock price of $7.26 and trailing twelve-month earnings per share of $0.48.
The current P/E is 94% below its 5-year average of 213.2x. Over the past five years, PBYI's P/E has ranged from a low of 3.5x to a high of 2820.0x, placing the current valuation at the 57th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, PBYI trades at a 47% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, PBYI trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PBYI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PBYI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 15.5 | - | +1747% | |
| $5B | 8.3Lowest | - | +264% | |
| $4B | 9.9 | - | +68% | |
| $12B | 16.6 | 0.32Best | +58% | |
| $151B | 19.5 | - | -4% | |
| $283B | 27.9 | 1.28 | +191% | |
| $92B | 29.2 | 0.75 | +15% | |
| $2B | 36.3 | 4.85 | +1883%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
PBYI Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $6.39 | $0.48 | 13.3x | -94% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $5.95 | $0.61 | 9.8x | -95% |
| FY2025 Q3 | $5.31 | $0.74 | 7.2x | -97% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $3.43 | $0.98 | 3.5x | -98% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $2.96 | $0.77 | 3.9x | -98% |
| FY2024 Q4 | $3.05 | $0.61 | 5.0x | -98% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $2.55 | $0.48 | 5.4x | -97% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $3.26 | $0.19 | 17.5x | -92% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $5.30 | $0.33 | 16.3x | -92% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $4.33 | $0.45 | 9.5x | -96% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $2.63 | $0.07 | 35.2x | -83% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $3.09 | $0.11 | 27.6x | -87% |
Average P/E for displayed period: 213.2x
See PBYI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PBYI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PBYI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPBYI — Frequently Asked Questions
Quick answers to the most common questions about buying PBYI stock.
Is PBYI stock overvalued or undervalued?
PBYI trades at 11.9x P/E, below its 5-year average of 213.2x. At the 57th percentile of historical range, the stock is priced at a discount to its own history.
How does PBYI's valuation compare to peers?
Puma Biotechnology, Inc. P/E of 11.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is PBYI's PEG ratio?
PBYI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2026.